Trial Profile
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Brexucabtagene autoleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ZUMA-3
- Sponsors Kite Pharma
- 12 Dec 2023 Results of Real-World Outcomes of Brexucabtagene Autoleucel (brexu-cel) for Relapsed or Refractory (R/R) Adult B-Cell Acute Lymphoblastic Leukemia, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 14 Nov 2023 Status changed from active, no longer recruiting to completed.
- 06 Oct 2023 Results of retrospective pooled analysis of 3 clinical trials( ZUMA-3, INO-VATE, and TOWER)estimating the relative treatment effects of brexu-cel versus inotuzumab ozogamicin (InO), blinatumomab (blina), and chemotherapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients, published in the Advances in Therapy.